In the coming years, the global obesity drug market may continue shifting toward triple agonists, oral peptide drugs, long-acting therapies, and next-generation peptide engineering technologies
The future of oral GLP-1 medications The oral semaglutide drops space is evolving rapidly
Given the emerging concern around potential muscle loss, strategies to mitigate reductions in FFM during pharmacologically induced BW loss should be prioritized
In 2025, Williams opened up about her experience taking Zepbound, citing not only weight loss but improved health overall
Development and approval of rybelsus (oral semaglutide): ushering in a new era in peptide delivery
You may have a little redness or irritation at the injection site, which is why we recommend rotating the site